TY - JOUR
T1 - Expression and mutation analysis of her2 in head and neck squamous cell carcinoma
AU - Ali, Mahmoud Al Sheikh
AU - Gunduz, Mehmet
AU - Gunduz, Esra
AU - Tamamura, Ryo
AU - Beder, Levent Bekir
AU - Katase, Naoki
AU - Hatipoglu, Omer Faruk
AU - Fukushima, Kunihiro
AU - Yamanaka, Noboru
AU - Shimizu, Kenji
AU - Nagatsuka, Hitoshi
N1 - Funding Information:
Keywords: Her2, Immunohistochemistry, Mutation, Head and neck cancer Correspondence to: Mehmet Gunduz, MD, PhD Department of Oral Pathology and Medicine, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikatacho, Okayama 700-8525, Japan. email: mehmet.gunduz@gmail.com This work was partially supported by grants-in-aid for scientific researches from the Ministry of Education, Culture, Sports, Science and Technology [21592326 (to HN), 20791337 (to RT)].
PY - 2010/5
Y1 - 2010/5
N2 - We analyzed mutation and expression status of human epidermal growth factor receptor 2 (Her2) in head and neck squamous cell carcinoma (HNSCC) using single strand conformation polymorphism (SSCP) mutation analysis and immunohistochemistry (IHC). Mutations were absent in all 85 cases. Out of 57 cases available for IHC, Her2 protein expression was negative (0) in 40 tumors (70). Seventeen tumors (29.8) expressed Her2, among these 13 tumors (22.8%) showed a weak (+1) expression and 4 (7%) showed a moderate expression (+2), none showed a strong (+3) expression. There was not a significant association between expression and any of the patients' clinical variables or prognosis. Our results suggest that Her2 may not be useful as a molecular target in HNSCC.
AB - We analyzed mutation and expression status of human epidermal growth factor receptor 2 (Her2) in head and neck squamous cell carcinoma (HNSCC) using single strand conformation polymorphism (SSCP) mutation analysis and immunohistochemistry (IHC). Mutations were absent in all 85 cases. Out of 57 cases available for IHC, Her2 protein expression was negative (0) in 40 tumors (70). Seventeen tumors (29.8) expressed Her2, among these 13 tumors (22.8%) showed a weak (+1) expression and 4 (7%) showed a moderate expression (+2), none showed a strong (+3) expression. There was not a significant association between expression and any of the patients' clinical variables or prognosis. Our results suggest that Her2 may not be useful as a molecular target in HNSCC.
KW - Head and neck cancer
KW - Her2
KW - Immunohistochemistry
KW - Mutation
UR - http://www.scopus.com/inward/record.url?scp=77952213693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952213693&partnerID=8YFLogxK
U2 - 10.3109/07357900903476778
DO - 10.3109/07357900903476778
M3 - Article
C2 - 20014947
AN - SCOPUS:77952213693
VL - 28
SP - 495
EP - 500
JO - Cancer Investigation
JF - Cancer Investigation
SN - 0735-7907
IS - 5
ER -
